TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01098383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-Choline Esterase Inhibitors and Choline supplements
Description: Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indistinguishable placebo tablets, matching both donepezil and choline
Description: Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
Study: NCT06271135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPILLARY REPAIR SERUM 30ml
Description: Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
Study: NCT05640375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Single dose, 1 mg/kg
Study: NCT00902252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usual
Description: All subjects will wear their usual pouching system for the first 21 days of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natura®
Description: All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitala™
Description: After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215).
Study: NCT02851953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqueduct-100
Study: NCT00850005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: 2 g/kg divided over five days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Same volume as experimental arm
Study: NCT01272739

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHBG-10
Description: 500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken 15 minutes prior to the three main meals of the day
Study: NCT00646100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcatheter arterial chemoembolization
Description: chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
Study: NCT01629693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
Study: NCT01259700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-risk patient standardized management package
Description: A primary-care based high cardiovascular risk management package delivered by village doctors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-risk patient standardized management package
Description: A primary-care based high cardiovascular risk management package delivered by village doctors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based salt reduction program
Description: A community-based salt reduction program delivered mainly by community health educators

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based salt reduction program
Description: A community-based salt reduction program delivered mainly by community health educators
Study: NCT01189071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
Study: NCT02987504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samalizumab
Description: Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
Study: NCT00415311

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
Description: Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
Description: Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
Description: Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
Study: NCT01925807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Intervention
Description: The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
Study: NCT02843347

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
Study: NCT03791619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Higher Cylinder Toric IOL
Description: Symfony Toric models ZXT300 and ZXT375 IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower Cylinder Toric IOL
Description: Symfony Toric model ZXT150 IOL
Study: NCT02046369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone flexibly dosed 20-80 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator once daily
Study: NCT01529749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF + Losartan
Description: EFV/FTC/TDF --\> oral, 600/200/245 mg, od Losartan --\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/FTC/TDF
Description: 600/200/245 mg, od, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF + MK-0518
Description: FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF+MK-0518+Losartan
Description: FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral Losartan --\> -\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
Study: NCT01005680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
Study: NCT00583245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait training with physical therapist 2/week for 3 months
Study: NCT05734170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia Seeds and instant oatmeal breakfast
Description: The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cheerio Breakfast
Description: Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
Study: NCT05413187

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Olive oil and Chlorophyl
Study: NCT03874000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Given IV
Study: NCT05734170

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Instant Oatmeal breakfast
Description: The second group was assigned to consume one packet of instant oatmeal for 30 days.
Study: NCT04768023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvit D3
Description: Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching amount of vegetable oil to the vitamin D3.
Study: NCT02684669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: active drug infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo comparator
Study: NCT04297553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAPA-Fresh
Description: Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAPA-Freeze-only
Description: Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
Study: NCT02623426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant 0.7 mg
Description: Standard preparation as described for intravitreal injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Methotrexate 400 µg
Description: Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumab 0.5 mg
Description: Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Study: NCT04337515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMacs®
Description: CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
Study: NCT01995006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metamizole
Description: metamizol tablets (500mg): 1000mg TID during 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets (500mg): 500 mg BID during 7 days
Study: NCT02700074

Intervention type: OTHER
Intervention: No Intervention
Description: Intervention is not a part of this study.

Intervention type: OTHER
Intervention: No Intervention
Description: Intervention is not a part of this study.

Intervention type: OTHER
Intervention: No Intervention
Description: Intervention is not a part of this study.

Intervention type: OTHER
Intervention: No Intervention
Description: Intervention is not a part of this study.
Study: NCT02535247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copanlisib
Study: NCT05021588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid and anticoagulants according to different protocols.
Description: As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid and anticoagulants according to different protocols.
Description: As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid and anticoagulants according to different protocols.
Description: As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
Study: NCT01576627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc citrate
Description: 10 mg of zinc as either zinc citrate
Study: NCT03874000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study: NCT01383070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactational Counseling by Cell phone
Description: The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Lactational Counseling by Cell phone
Description: The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
Study: NCT02160873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chocolate milk
Description: 12 oz, 7-8 hours prior to exercise trial (night before)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: flavor-matched placebo
Description: 12 oz, non-caloric flavor-matched placebo
Study: NCT01965067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state
Study: NCT01509859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA proximal femur nail device (Synthes)
Description: synthes PFNA proximal femur nail device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTERTAN proximal femur nail device (Smith&Nephew)
Description: Smith\&Nephew INTERTAN proximal femur nail device
Study: NCT00686400

Intervention type: OTHER
Intervention: TAU = treatment as usual
Description: medication and psychosocial interventions to be chosen by treating psychiatrist
Study: NCT01575340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil encapsuled
Description: 2 g/d (4 capsules of 500 mg)for 9 weeks
Study: NCT02393313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rayner T-flex Toric IOLs
Study: NCT00977262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of saturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of saturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of saturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of monounsaturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of monounsaturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of monounsaturated fat
Study: NCT01576627

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Gluconate
Description: 10 mg of zinc as either zinc gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc oxide
Description: 10 mg of zinc as either zinc oxide
Study: NCT03012620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Treatment
Study: NCT02018042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug.
Study: NCT04507789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients. The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area. Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine radiotherapy protokol
Description: This intervention is only an observation to patients during their routine radiotherapy protocol. There will be no exercise intervention for the upper extremity for the patient in this group.
Study: NCT03515837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: IV infusion
Study: NCT02179762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vigorous exercise intervention - cybercycling
Description: perform HIIT exercise on cybercycles aided by electronic racing and other games

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Logs
Description: The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.